Abivax Stock Jumps 78% on Positive Ulcerative Colitis Phase 3 Data
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
abivaxobefazimod
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Abivax SA's stock price surged 78% in European trading on June 30, 2026, after the clinical-stage biotech announced its lead drug candidate, obefazimod, successfully met all primary and secondary endpoints in its Phase 3 induction study for moderately to severely active ulcerative colitis. The data release triggers a major repricing of the stock and establishes the oral medication as a credible challenger in the lucrative inflammatory bowel disease therapeutic market. The company reported statistically significant results for clinical remission and endoscopic improvement, key regulatory endpoints required for future drug approval applications to global health authorities.
The inflammatory bowel disease treatment market is valued at approximately $26 billion globally, with ulcerative colitis representing a significant portion of that addressable patient population. Current standard-of-care treatments include anti-TNF biologics like Humira, JAK inhibitors like Xeljanz, and newer biologic therapies, but many patients fail to achieve or maintain remission, creating substantial demand for novel mechanisms. The last major positive Phase 3 readout in this space occurred in September 2025, when Telavant's RVT-3101 demonstrated strong efficacy, sending its parent company's stock up 65% in a single session.
Abivax's announcement comes during a period of renewed investor interest in mid-cap biotech stocks, particularly those with late-stage assets that address large markets with unmet medical needs. The European Medicines Agency had already granted obefazimod Priority Medicines designation in 2025, signaling regulatory recognition of its potential. The successful trial results validate the drug's mechanism of action, which modulates mRNA stability to reduce inflammation through a novel pathway distinct from existing therapies.
Abivax's stock reached €42.18 per share at its session peak, up from its previous close of €23.70, representing a single-day market capitalization increase of approximately €450 million. Trading volume exceeded 3.5 million shares, more than 15 times the 30-day average volume of 225,000 shares. The Phase 3 trial demonstrated that 26.5% of patients receiving obefazimod 25mg achieved clinical remission at week 10 compared to 13.5% in the placebo group, representing a statistically significant absolute difference of 13.0%.
| Endpoint | Obefazimod 25mg | Placebo | P-value |
|---|---|---|---|
| Clinical Remission | 26.5% | 13.5% | p<0.001 |
| Endoscopic Improvement | 41.2% | 22.0% | p<0.001 |
The safety profile appeared favorable with low discontinuation rates due to adverse events at 3.8% in the treatment arm versus 2.9% in placebo. These efficacy numbers compare favorably with recently approved therapies like Pfizer's etrasimod, which demonstrated a 12.7% absolute improvement over placebo in its Phase 3 program. The data support Abivax's planned submission for marketing authorization in both the United States and European Union in 2027.
The positive data creates competitive pressure on established ulcerative colitis market leaders including AbbVie (ABBV), Johnson & Johnson (JNJ), and Pfizer (PFE), whose blockbuster drugs may face share erosion if obefazimod gains approval. Pure-play inflammatory disease companies like Bristol Myers Squibb (BMY) and Merck (MRK) could see increased interest in their pipeline assets as investor focus shifts to novel mechanisms in immunology. The news provides a tailwind for the broader biotech sector (XBI), particularly other companies developing oral therapies for autoimmune conditions.
The primary risk factor remains the ongoing maintenance phase of the trial, which must demonstrate obefazimod's ability to sustain remission over longer treatment periods to achieve commercial success. Safety monitoring will continue through the extension study, though the initial data showed no concerning signals. Hedge funds and specialist healthcare funds established significant long positions during the pre-data period, while retail investors largely remained on the sidelines until after the results confirmation.
Investors should monitor the completion of the ongoing maintenance phase study, with top-line results expected in the fourth quarter of 2026. The company plans to meet with the U.S. Food and Drug Administration in Q1 2027 to discuss regulatory filing strategies based on the complete dataset. Key clinical milestones include presentation of the full results at a major medical conference such as the United European Gastroenterology Week in October 2026.
Stock performance will likely hinge on additional data releases supporting obefazimod's durability and safety profile over time. Technical resistance levels emerge around the €45-€48 price range where previous institutional selling occurred in 2025. Support established around €35 represents the new base following the data announcement. Partnership announcements or potential acquisition interest could provide additional catalysts before regulatory submissions.
Obefazimod works through a novel mechanism by modulating the stability of pro-inflammatory mRNA transcripts, particularly targeting TNFα, which differs fundamentally from antibody-based biologics that block specific cytokines or JAK inhibitors that work intracellularly. This approach potentially offers both efficacy and convenience advantages as an oral therapy with a differentiated safety profile compared to immunosuppressive alternatives.
Analyst models suggest obefazimod could achieve peak sales between $1.5-2.5 billion annually assuming approval in 2028, representing approximately 8-12% of the current ulcerative colitis market. Market penetration would likely be strongest among patients who have failed first-line therapies or prefer oral administration over injectable biologics, with potential expansion into Crohn's disease creating additional upside.
Positive late-stage readouts from companies like Abivax typically improve investor sentiment toward preclinical and clinical-stage biotechs, particularly those working on novel mechanisms in immunology and inflammation. Successful outcomes demonstrate that venture capital and public market funding can yield significant returns, potentially increasing capital allocation to the sector through both equity offerings and partnership deals with larger pharmaceutical companies.
Abivax's successful Phase 3 trial establishes obefazimod as a credible threat to established ulcerative colitis market leaders.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.